scholarly journals Long-term proton pump inhibitor usage and the association with pancreatic cancer in Sweden

2019 ◽  
Vol 55 (4) ◽  
pp. 453-461 ◽  
Author(s):  
Nele Brusselaers ◽  
Omid Sadr-Azodi ◽  
Lars Engstrand
Keyword(s):  
Pancreatic Cancer ◽  
Receptor Antagonist ◽  
Proton Pump ◽  
Population Based ◽  
H2 Receptor Antagonist ◽  
H2 Receptor ◽  
Increased Risk ◽  
History Of ◽  
Rate Ratios

Abstract Background The long-term safety of proton pump inhibitors (PPIs) is increasingly questioned. The aim of our study was to assess the risk of pancreatic cancer among long-term PPI users in Sweden. Methods This population-based nationwide Swedish cohort study including 796,492 adult long-term PPI users has been used to calculate the standardized incidence rate ratios (SIRs) and 95% confidence intervals (CI) for pancreatic cancer, stratifying by indications of use, age, sex, and duration of use. The risk among all 20,210 long-term H2-receptor antagonist users was assessed as comparison. Results Pancreatic cancer was found in 1733 long-term PPI users, and 25 H2-receptor antagonist users. For PPI users, the risk of pancreatic cancer was increased overall (SIRs = 2.22; 95% CI 2.12–2.32) and in all subgroup analyses, with the highest risk among PPI-users younger than 40 years (SIR = 8.90, 95% CI 4.26–16.37), and among individuals with a history of Helicobacter pylori (SIR = 2.99, 95% CI 2.54–3.49). After the first year after enrolment (during which PPI use may be because of early symptoms of pancreatic cancer), the risk remained increased over time, with SIR = 1.57 (95% CI 1.38–1.76) after 5 years. No associations were found for H2-receptor antagonists (SIR = 1.02, 95% CI 0.66–1.51). Conclusions This large study showed an increased risk of pancreatic cancer in long-term users of PPIs in Sweden, in particular among the youngest users.

Does long-term medication with a proton pump inhibitor induce a tolerance to H2 receptor antagonist?

2007 ◽  
Vol 42 (4) ◽  
pp. 275-278 ◽  
Author(s):  
Hiroshi Hashimoto ◽  
Tetsuya Kushikata ◽  
Mihoko Kudo ◽  
Kazuyoshi Hirota
Keyword(s):  
Proton Pump Inhibitor ◽  
Receptor Antagonist ◽  
Proton Pump ◽  
H2 Receptor Antagonist ◽  
H2 Receptor

Administration of H2 Receptor Antagonist With Proton Pump Inhibitor Is Effective for Long-term Control of Refractory Reflux Esophagitis

2004 ◽  
Vol 38 (3) ◽  
pp. 297-298 ◽  
Author(s):  
Kyoichi Adachi ◽  
Yoshinori Komazawa ◽  
Takafumi Mihara ◽  
Hirofumi Fujishiro ◽  
Shunji Ishihara ◽  
...  
Keyword(s):  
Proton Pump Inhibitor ◽  
Receptor Antagonist ◽  
Proton Pump ◽  
Reflux Esophagitis ◽  
H2 Receptor Antagonist ◽  
H2 Receptor

scholarly journals Long-Lasting Increased Risk of Human Papillomavirus–Related Carcinomas and Premalignancies After Cervical Intraepithelial Neoplasia Grade 3: A Population-Based Cohort Study

2017 ◽  
Vol 35 (22) ◽  
pp. 2542-2550 ◽  
Author(s):  
Renée M.F. Ebisch ◽  
Dominiek W.E. Rutten ◽  
Joanna IntHout ◽  
Willem J.G. Melchers ◽  
Leon F.A.G. Massuger ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Cervical Intraepithelial Neoplasia ◽  
Incidence Rate ◽  
Intraepithelial Neoplasia ◽  
Population Based ◽  
Cervical Intraepithelial Neoplasia Grade ◽  
Increased Risk ◽  
History Of ◽  
Grade 3 ◽  
Rate Ratios

Purpose The aim of this study was to determine the risk of human papillomavirus (HPV)–related carcinomas and premalignancies in women diagnosed with cervical intraepithelial neoplasia grade 3 (CIN3). Knowledge of this risk is important to preventing the development and progression of other HPV-related premalignancies and carcinomas, by considering prophylactic HPV vaccination and/or by paying increased attention to other HPV-related carcinomas and premalignancies when CIN3 is identified. Methods Women diagnosed with a CIN3 between 1990 and 2010 were identified from the Dutch nationwide registry of histopathology and cytopathology (PALGA) and matched with a control group of women without CIN3. Subsequently, all cases of high-risk (hr) HPV–associated high-grade lesions and carcinomas in the anogenital region and oropharynx between 1990 and 2015 were extracted. Incidence rate ratios were estimated for carcinomas and premalignancies of the vulva, vagina, anus, and oropharynx. Results A total of 178,036 women were identified: 89,018 with a previous diagnosis of CIN3 and 89,018 matched control subjects without a history of CIN3. Women with a history of CIN3 showed increased risk of HPV-related carcinomas and premalignancies, with incidence rate ratios of 3.85 (95% CI, 2.32 to 6.37) for anal cancer, 6.68 (95% CI, 3.64 to 12.25) for anal intraepithelial neoplasia grade 3, 4.97 (95% CI, 3.26 to 7.57) for vulvar cancer, 13.66 (93% CI, 9.69 to 19.25) for vulvar intraepithelial neoplasia grade 3, 86.08 (95% CI, 11.98 to 618.08) for vaginal cancer, 25.65 (95% CI, 10.50 to 62.69) for vaginal intraepithelial neoplasia grade 3, and 5.51 (95% CI, 1.22 to 24.84) for oropharyngeal cancer. This risk remained significantly increased, even after long-term follow-up of up to 20 years. Conclusion This population-based study shows a long-lasting increased risk for HPV-related carcinomas and premalignancies of the anogenital and oropharyngeal region after a CIN3 diagnosis. Studies that investigate methods to prevent this increased risk in this group of patients, such as intensified screening or vaccination, are warranted.

IMMUNOLOGICAL STUDIES AFTER LONG-TERM H2-RECEPTOR-ANTAGONIST THERAPY

The Lancet ◽  
1977 ◽  
Vol 310 (8038) ◽  
pp. 616 ◽  
Author(s):  
B.E. De Pauw ◽  
C.B.H.W. Lamers ◽  
D.J.Th Wagener ◽  
H.P.M. Festen
Keyword(s):  
Receptor Antagonist ◽  
H2 Receptor Antagonist ◽  
Antagonist Therapy ◽  
H2 Receptor

scholarly journals Reduced risk of skin cancer and internal malignancies in vitiligo patients: a retrospective population-based cohort study in Taiwan

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Yu-Ching Weng ◽  
Hsiu J. Ho ◽  
Yi-Ling Chang ◽  
Yun-Ting Chang ◽  
Chun-Ying Wu ◽  
...  
Keyword(s):  
Cohort Study ◽  
Cell Carcinoma ◽  
Systemic Disease ◽  
Population Based ◽  
Incidence Rates ◽  
Research Database ◽  
Hazard Ratios ◽  
History Of ◽  
Rate Ratios

AbstractThe relationship between cancer and vitiligo has been explored but with inconsistent results. To examine the long-term cancer risk in vitiligo patients, we conducted a retrospective nationwide cohort study. From the National Health Insurance Research Database of Taiwan, a total of 13,824 vitiligo patients were identified and matched with 55,296 reference subjects without vitiligo by age, gender, and propensity score estimated by major comorbidities from 1997 to 2013. Demographic characteristics and comorbidities were compared between these two groups. Incidence rate ratios and hazard ratios (HRs) were calculated to examine cancer risks. The 16-year incidence rates of overall cancers were 621.06 (566.56–675.55) and 726.99 (697.24–756.74) per 100,000 person-years in the vitiligo and reference groups. Patients with vitiligo showed a significantly decreased risk of overall cancers [adjusted HR, 0.85; 95% confidence interval (CI), 0.77 to 0.93, p < 0.001] compared with reference subjects without vitiligo after adjusting for age, sex, comorbidities, and treatments. The risks of basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) were significantly reduced (adjusted HR 0.21, 95% CI 0.11–0.38, p < 0.001), as well as internal malignancies (adjusted HR 0.89, 95% CI 0.81–0.99, p = 0.026). The results were consistent across different subgroups of patients, including male gender, ages more than 40 years, and those receiving long-term systemic disease-modifying antirheumatic drugs and phototherapies. Information related to phenotype, disease duration, vitiligo lesion sites, family history of vitiligo or cancer, occupation, and personal lifestyle was not included in the database. Vitiligo is associated with reduced risks of BCC and SCC, as well as internal malignancies.

Sign in / Sign up

Export Citation Format

Share Document